Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Stomach Neoplasms × bemarituzumab × Clear all

Phase

Phase 3 2 Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Adenocarcinoma 2 Stomach Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Oxaliplatin 154 Capecitabine 104 Fluorouracil 91 Docetaxel 77 Cisplatin 76 S 1 (combination) 74 Leucovorin 63 Paclitaxel 52 Irinotecan 51 pembrolizumab 34 Trastuzumab 31 apatinib 29 sintilimab 28 Bevacizumab 20 Surgical Procedures, Operative 19 Radiotherapy 19 camrelizumab 15 Ramucirumab 14 Nivolumab 14 titanium silicide 13 tislelizumab 13 Drug Therapy 13 Hyperthermic Intraperitoneal Chemotherapy 12 Folfox protocol 12 Epirubicin 12 Cetuximab 12 Tegafur 10 Carboplatin 10 XELOX 9 HMPL-013 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03694522 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 2 Completed

155 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡